Givotan: Approved Therapeutic Uses

Givotan is a prescription medication utilized in the management of diarrhea resulting from specific protozoan infections. Its primary therapeutic indication is the treatment of diarrhea caused by two distinct parasites: Giardia lamblia and Cryptosporidium parvum.

This medication is approved for use in adults and children aged 12 years and older for the treatment of both Giardia lamblia and Cryptosporidium parvum infections, as well as in children 1 to 11 years of age for these conditions. The medication is generally indicated for use in immunocompetent individuals, meaning those with a healthy immune system.

Who Can and Cannot Use Givotan?

Regulatory documentation strictly defines the population eligibility for Givotan (Nitazoxanide) based on age, formulation, and certain pre-existing conditions.

Eligibility Scope

Category	Eligibility Rule/Restriction
Contraindicated Populations	Patients with a prior hypersensitivity to nitazoxanide or any ingredient in the formulation.
Age-related Eligibility Rules	The oral suspension is approved for children mathbf1 to mathbf11 years old. The tablet form is approved only for patients mathbf12 years of age and older. Safety and efficacy have not been established in infants younger than mathbf1 year.
Condition-specific Limitations	HIV-infected or Immunodeficient Patients are a restricted group; the medicine has not been shown to be effective for Cryptosporidium parvum in these individuals. Use requires caution in patients with compromised renal or hepatic function as pharmacokinetics have not been studied in these populations.
Pregnancy and Lactation Status	For pregnancy, use is warranted only if clearly needed, as no human data exist to inform a drug-associated risk. The active metabolite is excreted in human milk, leading regulators to advise caution during lactation.

Connection to the Overall Eligibility Profile

The eligibility profile is structured by a single absolute contraindication (hypersensitivity) and clear age-based exclusions tied to the drug's formulation. The primary restrictions relate to a lack of established efficacy in immunodeficient individuals and insufficient data concerning the drug's use in patients with impaired renal or hepatic function, necessitating conditional use in these specific populations.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Givotan (Nitazoxanide) as described in regulatory documents. The primary interactions relate to plasma protein binding displacement and the influence of food on drug exposure.

Drug-Drug Interaction Profile

Interaction Type	Official Regulatory Statement
Protein Binding Displacement	The active metabolite, tizoxanide, is highly bound to plasma proteins (over 99.9%). Co-administration with other highly protein-bound medicinal products that have narrow therapeutic indices (e.g., warfarin) may lead to competition and potential displacement, altering the exposure of the co-administered drug.
Metabolic Interactions	No clinically significant interactions involving the inhibition or induction of Cytochrome P450 (CYP) enzymes are expected or documented in regulatory labeling.
Contraindicated Combinations	No substances are explicitly listed as formally contraindicated for co-administration based on drug-drug interaction risk.

---

Drug-Food and Population-Specific Interactions

Co-administration of Givotan tablets with food is officially documented to significantly increase the systemic exposure to tizoxanide. Regulatory data shows the tablet's maximum plasma concentration (Cmax) and the overall extent of absorption (AUC) are increased by approximately 50% and two-fold, respectively.

Specific caution related to the protein binding displacement risk is noted for patients with hepatic or renal impairment. Since the pharmacokinetics of Givotan have not been studied in these populations, altered clearance could potentially lead to increased plasma levels of the active metabolite, which would heighten the risk of displacement interactions.

How Givotan Works: Mechanism of Action

Blocking Pathogen Energy Production

Givotan's core action relies on its active form, which functions as an inhibitor of the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme system in susceptible anaerobic microorganisms. This targeted interference prevents these organisms from generating essential energy (ATP), leading to metabolic deprivation and inactivation.

Disrupting Microbial Genetic and Cellular Structure

In a second mechanistic domain, the drug's active form causes direct damage to the pathogen's DNA and RNA and compromises the integrity of its cell membranes. This suppresses microbial replication and structural stability, resulting in functional loss and eventual clearance from the host system.

Reducing Systemic Microbial Load

These combined cellular mechanisms—energy blockade and structural damage—lead to a reduction in the population of active, replicating pathogens. The resulting physiological effect is the reduction of systemic factors related to microbial activity, facilitating the restoration of baseline function within affected tissues.

Givotan (nitazoxanide) is an oral-only medication intended for administration as a fixed course over a short duration. The general principle of use involves taking the medicine every 12 hours (twice daily) for 3 consecutive days to complete the prescribed regimen. The medication must be administered with food for both the tablet and oral suspension forms, as this condition is necessary for proper systemic exposure.

---

Dosing and Dosage Forms

The dosing regimen is differentiated by age group and administered via two non-interchangeable pharmaceutical forms. The 500 mg tablet is restricted to patients 12 years of age and older; children aged 1 to 11 years must use the oral suspension form. Prior to administering a dose of the oral suspension, the bottle must be shaken well to ensure uniform concentration.

Age Group	Dose per Administration	Required Dosage Form
Adults & Adolescents (ge 12 years)	500 mg	Tablet or Oral Suspension
Children 4 to 11 years	200 mg	Oral Suspension only
Children 1 to 3 years	100 mg	Oral Suspension only

These instructions define the standardized procedure for using the medicine. Safety and efficacy have not been established for children under one year of age. Furthermore, due to the lack of formal study data, caution should be applied when administering Givotan to populations with significant hepatic or renal impairment.

Research Evidence / Overview of Studies for Givotan

The research on Givotan (nitazoxanide) is based on formal clinical trials and scientific reviews that explored its use for specific parasitic infections. These studies help show what has been observed so far regarding patterns measured in patient groups under controlled conditions. This overview summarizes the publicly available evidence, focusing on the type of research conducted and areas where certainty remains low or data are still emerging.

---

Evidence for use in Diarrhea Caused by Cryptosporidium parvum

The evidence base comes from randomized, double-blind clinical trials (RCTs). These studies compared Givotan against a placebo and were used in research exploring how short-term symptoms change over time. Research examined outcomes related to physical discomfort (diarrhea resolution) and measured parasitological eradication (clearance of C. parvum oocysts from stool). Studies focused heavily on immunocompetent individuals, where patterns were observed showing the clearance of parasites from stool. However, findings were mixed in immunodeficient/HIV-infected patients, and data for this group remain insufficient to confirm consistent clinical patterns.

---

Evidence for use in Diarrhea Caused by Giardia lamblia

Research also relies on Randomized Controlled Trials (RCTs), comparing Givotan against a placebo and other medicines used in the treatment of Giardiasis. Studies monitored non-immunodeficient children and adults, exploring both patient-reported outcomes and objective measures of parasitological eradication. Findings describe patterns observed in these groups, including measurements of parasite clearance from the stool. However, follow-up durations were limited. The sustained response (how often infection recurs) is not fully established, and data for certain groups (such as adults where Giardia was the sole pathogen) remain insufficient.

---

Limitations and Research Gaps

Key limitations include that sample sizes were modest in some pivotal trials, which may affect the ability to generalize findings. The most significant research gap is the uncertainty surrounding the immunodeficient patient population. The evidence quality varies across studies, and long-term effects are not fully established. Study results reflect the specific conditions under which they were conducted and do not provide individual predictions.

Common questions about Givotan (FAQ)

---

Q: What are the key differences between the tablet and oral suspension forms?

Regulatory documents state that the oral suspension and the tablets are not considered interchangeable (bioequivalent). This means they do not produce the same level of drug exposure in the bloodstream. Due to these differences, the tablet is approved only for patients 12 years and older, while the suspension can be used by children aged 1 year and older.

---

Q: Can Givotan be used during pregnancy or breastfeeding?

Official product information advises caution during pregnancy and breastfeeding. There are no adequate human studies to determine if Givotan poses a risk during pregnancy, so its use is generally restricted to situations when clearly necessary. Studies show that the active compound, tizoxanide, is excreted in human milk, which is why caution is advised for nursing mothers.

---

Q: What is the specific dosing for a child who is 8 years old?

The official dosing schedule for children between the ages of 4 and 11 is based on the oral suspension form. This dose is administered twice a day (every 12 hours) with food, as specified in the standardized regimen for this age group.

---

Q: What is the required length of treatment?

According to the official prescribing information, the standard course of treatment for the approved parasitic infections is a short, fixed course. The regimen is typically completed in 3 consecutive days.

---

Q: Is Givotan effective against bacterial infections, or is it only for parasites?

This medicine is primarily classified as an antiprotozoal agent and is indicated for the treatment of diarrhea caused specifically by the parasites Giardia lamblia or Cryptosporidium parvum. The official regulatory label does not include indications for treating general or common bacterial infections.

---

Q: What should I do if I miss a dose of Givotan?

Official patient instructions typically describe the procedure for a missed dose, which involves taking it as soon as it is remembered unless it is almost time for the next dose. If it is almost time for the next dose, the missed dose is usually skipped, and the regular schedule is continued. Instructions generally state that a double dose should not be taken.

---

Q: How quickly does Givotan start to work after the first dose?

Studies on the drug’s absorption show that the active circulating form, tizoxanide, is rapidly absorbed after administration. It typically reaches its highest concentration in the bloodstream within 1 to 4 hours after the first oral dose is taken.

---

The official storage and disposal requirements for nitazoxanide (Givotan) are defined by regulatory agencies to maintain product stability and ensure public safety.

Storage Conditions

Requirement	Official Statement
Temperature	Store at Controlled Room Temperature 25 C (77 F); excursions permitted between 15 C and 30 C (59 F and 86 F).
Handling	Keep from freezing. Store away from excess heat, moisture, and direct light.
Container	Keep the medicine in a closed container, with the lid tightly closed.
Stability	The reconstituted oral suspension is stable for and must be discarded after 7 days.

Disposal and Safety

All nitazoxanide products must be stored out of the sight and reach of children. Unused oral suspension that has been mixed for longer than seven days must be promptly discarded. Unused or expired medicine should be disposed of by consulting a healthcare professional or following local environmental regulations.